Damora Therapeutics
DMRA
11 hedge funds and large institutions have $442K invested in Damora Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
10% more funds holding
Funds holding: 10 → 11 (+1)
0.05% more ownership
Funds ownership: 10.76% → 10.81% (+0.05%)
33% less capital invested
Capital invested by funds: $661K → $442K (-$218K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.46K |
| 3 |
Renaissance Technologies
New York
|
+$1.41K |
| 4 |
Squarepoint
New York
|
+$1.33K |
| 5 |
Barclays
London,
United Kingdom
|
+$627 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$57.4K |
| 2 |
JP Morgan Chase
New York
|
-$466 |
| 3 |
Morgan Stanley
New York
|
-$465 |
DMRA Hedge Fund Activity: Q1 2025 in Review
11 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q1 2025, worth a combined $442K — down 33% from $661K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DMRA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $50.5K. The largest seller was UBS Group, cutting an estimated $57.4K.
- 11 institutional investors held Damora Therapeutics (DMRA) as of Q1 2025, up from 10 in Q4 2024.
- Funds reported $442K of Damora Therapeutics stock for Q1 2025, down 33% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics positions in Q1 2025 and 2 closed out, a net change of +1 holder.
- The largest Damora Therapeutics buyer in Q1 2025 was Susquehanna International Group, an estimated $50.5K added.
- The largest Damora Therapeutics seller in Q1 2025 was UBS Group, an estimated $57.4K sold.
Based on aggregated 13F filings for Q1 2025.